POC1B (POC1 Centriolar Protein B)

Our study suggest that the manipulation of POC1B-AS1/miR-625-5p/FOXK1 pathway-mediated aggressiveness in CRC may offer an effective therapeutic target.

Functional enrichment and protein-protein interaction analyses revealed that CTSC regulates the ECM-integrin-PI3K-Akt signaling pathway, contributing to tumor cell proliferation and survival. The findings establish a multi-omics-based biomarker panel with strong diagnostic utility and mechanistic relevance, suggesting a potential framework for future translational validation in clinical cohorts.

Our findings suggest that PDAs are clinically and genetically heterogeneous diseases. Understanding the heterogeneity of PDA is critically important in determining its biological potential and facilitating optimal patient management.

Five patients were treated with matched targeted therapy, with three having durable benefit: (i) erlotinib for EGFR-altered tumor, followed by osimertinib/capmatinib when MET amplification emerged (first-line therapy); (ii) pralsetinib for RET fusion (fifth line); and (iii) dabrafenib/trametinib for BRAF N486_P490del (third line). Sustained therapeutic benefit can be achieved in a real-world setting in a subset of patients with advanced/metastatic KRAS-WT PDAC treated with chemotherapy-free matched targeted agents. Prospective studies are warranted.

The 10 autophagy-related lncRNAs are potential prognostic biomarkers. Compared with using age and tumour grade, this prognostic model is more predictive for the prognosis of endometrial cancer patients.

Therefore, a nomogram combined risk score, immune risk score with clinical information which is meaningful in univariate and multivariate Cox regression analysis is established to predict the overall survival (OS) of COAD patients. In general, the signature consisted of 15 pyroptosis-related lncRNAs and was proved to be associated with the immune landscape of COAD patients.

Additionally, age, pathological grade, FIGO stage, and risk status were all related to patient survival. We identified 12 immune-related lncRNAs affecting the prognosis of endometrial cancer, which may be useful as therapeutic targets and molecular biomarkers.